Quantifiable phenotypes associated with pre-infusion PSMA CAR T-cells in mCRPC also shared with CD19 CAR T-cell products in leukemia and lymphoma are potentially actionable by enriching desirable, or eliminating undesirable, cellular populations or functional states during ex vivo manufacturing. This evidence concerns the gene FOLH1 and leukemia.